Boston, MA 06/03/2013 (wallstreetpr) – The shares of Transition Therapeutics Inc. USA (NASDAQ:TTHI) had gained 9.48 percent to close at $3.35 per share for the last trading session on Friday. The shares of the company had been trading in the range of $3.03 to $3.40 per share during the day, before closing at $0.29 per share higher than previous close on Thursday. The shares of Transition Therapeutics Inc. USA (NASDAQ:TTHI) had recorded 52 week high price level of $3.84 per share and 52 week low price level of $1.78 per share.
Transition Therapeutics Inc. USA (NASDAQ:TTHI) is a bio pharmaceutical company which is focused on the development and commercialization of novel therapeutics for disease indications in large markets. The company presently has many therapeutic technologies in development which include ELND005 (AZD-103) for the treatment of Alzheimer’s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer’s disease, traumatic brain injury and intracerebral haemorrhage.
Further, Transition Therapeutics Inc. USA (NASDAQ:TTHI) also holds a wholly owned subsidiary, Waratah Pharmaceuticals Inc. to focus on the development and commercialization of ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.
The shares of Transition Therapeutics Inc. USA (NASDAQ:TTHI) had recently surged to heavy volumes with nearly 160,459 shares being traded on Friday, while the average trading volume for the company is at 141,458 shares per day. The company presently holds 26.92 million shares outstanding in the market.
